Study to Analyze the Aerobic Performance Efficacy of Chronic Intake With a β-alanine Supplement in Recreational Cyclists
NCT ID: NCT06167395
Last Updated: 2024-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
75 participants
INTERVENTIONAL
2023-12-04
2024-03-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Analyze the Efficacy of Acute Intake With a β-alanine Supplement in Recreational Cyclists
NCT06180512
The Efficacy β-Alanine Supplementation in Performance Outcomes of Road Professional Endurance Cyclists
NCT04427319
Safety Analysis of Chronic Intake of a β-alanine Supplement
NCT05334121
Acute Supplementation With Beta-Alanine Improves Performance in Aerobic-anaerobic Transition Zones in Endurance Athletes
NCT05096793
The Effects of an Acute Dose of a Betalain-rich Concentrate on Repeated-sprint Cycling Performance and Recovery.
NCT06274385
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The product to be consumed is beta alanine. Participants will consume the product for 30 days. They will have to take 4 intakes every three hours, being the first intake two hours after waking up.
The study subjects will have to make 2 visits to the laboratory. At the first and last visit, their aerobic performance will be evaluated by an incremental test to exhaustion with gas analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Beta Alanine high dose
Consumption for 30 days.
Beta Alanine high dose
Subjects should consume 4 intakes of 5 g of beta alanine every 3 hours each day.
Beta Alanine low dose
Consumption for 30 days.
Beta Alanine low dose
Subjects should consume 4 intakes of 2,5 g of beta alanine every 3 hours each day.
Control group
Consumption for 30 days.
Control product
Subjects should consume 4 intakes of 2,5 g of wheat semolina every 3 hours each day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Beta Alanine high dose
Subjects should consume 4 intakes of 5 g of beta alanine every 3 hours each day.
Beta Alanine low dose
Subjects should consume 4 intakes of 2,5 g of beta alanine every 3 hours each day.
Control product
Subjects should consume 4 intakes of 2,5 g of wheat semolina every 3 hours each day.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Perform tests without fatigue.
* Road bike training at least twice a week.
Exclusion Criteria
* Have a long-term injury that prevents you from training in the previous month.
* Inability to understand informed consent.
* Have consumed beta alanine in the three years prior to the start of the study.
* Consumption of other supplements that may alter performance.
18 Years
60 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad Católica San Antonio de Murcia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Francisco Javier López Román
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Catholic University of Murcia
Murcia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UCAMCFE-00031
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.